At Ferring we believe in the power of research and the need to go where the research takes us. We are passionate and curious about science.

Ferring invests heavily in the process of creating new medicines through its research and development centres and through research collaboration with scientific institutes, as well as biotechnology and pharmaceutical companies throughout the world.

Ferring’s R&D activities are focused on the development of first-in-class therapeutic peptides and proteins in our key therapeutic areas: reproductive health, urology, gastroenterology and endocrinology.

We strive to maintain our leadership by:

  • Focusing on novel peptide-based drugs and biotechnology derived medicines, such as recombinant proteins and other biologics
  • Investing in cutting-edge science and technology
  • Adapting existing peptide based medications to meet specific medical needs
  • Developing effective and patient friendly drug delivery systems.

Ferring has nine development sites around the world that include six product development laboratories in Copenhagen (Denmark), Parsippany (US), Glasgow (Scotland), Be’er Tuvia (Israel), Basel (Switzerland) and Mumbai (India).

The main pharmaceutical development hub is in Copenhagen. The Copenhagen and Parsippany sites drive and execute product innovation and development of new molecular entities as well as further development of our existing in-line products to better meet patient needs or address new disease areas.

Niederlassung Schweiz

Ferring AG Schweiz
6340 Baar ZG

Tel:  +41 41 768 96 96
Fax: +41 41 768 96 97

Vielen Dank für Ihren Besuch. Sie verlassen jetzt die Ferring AG (Schweiz) und werden direkt auf unsere globale Webseite weitergeleitet.